Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 18 10 2019
accepted: 22 12 2019
entrez: 4 2 2020
pubmed: 6 2 2020
medline: 25 4 2020
Statut: epublish

Résumé

To determine the effect of a linear gadolinium-based contrast agent (GBCA) on the signal intensity (SI) of the deep cerebellar nuclei (DCN) in a retrospective clinical study on dogs after multiple magnetic resonance (MR) examinations with intravenous injections of gadodiamide and LA-ICP-MS analysis of a canine cerebellum after gadodiamide administration. 15 client-owned dogs of different breeds and additionally 1 research beagle dog cadaver. In the retrospective study part, 15 dogs who underwent multiple consecutive MR imaging examinations with intravenous injection of linear GBCA gadodiamide were analyzed. SI ratio differences on unenhanced T1-weighted MR images before and after gadodiamide injections was calculated by subtracting SI ratios between DCN and pons of the first examination from the ratio of the last examination. Additionally, 1 research beagle dog cadaver was used for LA-ICP-MS (Laser ablation inductively coupled plasma mass spectrometry) analysis of gadolinium in the cerebellum as an add-on to another animal study. Descriptive and non-parametrical statistical analysis was performed and a p-value of < 0.05 was considered significant. No statistically significant differences of SI ratios, between DCN and pons, were detectable based on unenhanced T1-weighted MR images. LA-ICP-MS analyses showed between 1.5 to 2.5 μg gadolinium/g tissue in the cerebellum of the examined dog, 35 months after the last of 3 MRI examination with gadodiamide (two examinations at a dose of 1 x 0.1mmol/kg, last examination at a dose of 3 x 0.05mmol/kg). Although the retrospective MRI study did not indicate any visible effect of SI increase after multiple gadodiamide exposures, further studies based on LA-ICP-MS showed that the optical threshold was not reached for a potential visible effect. Gadolinium was detectable at a level of 1.5 to 2.5 μg gadolinium/g tissue by using LA-ICP-MS in the cerebellum 35 months after last MRI examination. The general importance of gadolinium retention of subvisible contents requires further investigation.

Identifiants

pubmed: 32012163
doi: 10.1371/journal.pone.0227649
pii: PONE-D-19-29091
pmc: PMC6996830
doi:

Substances chimiques

Contrast Media 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0227649

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Invest Radiol. 2016 Nov;51(11):683-690
pubmed: 27495187
Radiology. 2017 Dec;285(3):839-849
pubmed: 28873047
Radiology. 2015 Jun;275(3):803-9
pubmed: 25633504
Invest Radiol. 2014 Oct;49(10):685-90
pubmed: 24872007
Invest Radiol. 2017 Jul;52(7):389-395
pubmed: 28195932
Medicine (Baltimore). 2016 Sep;95(39):e4624
pubmed: 27684794
Radiology. 2017 Apr;283(1):195-204
pubmed: 27797676
Invest Radiol. 2016 Feb;51(2):73-82
pubmed: 26606549
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 19;6(1):e515
pubmed: 30568993
Radiology. 2014 Mar;270(3):834-41
pubmed: 24475844
AJNR Am J Neuroradiol. 2018 Mar;39(3):421-426
pubmed: 29419400
Invest Radiol. 2015 Aug;50(8):473-80
pubmed: 26107651
Radiology. 2015 Aug;276(2):616-7
pubmed: 26203714
AJNR Am J Neuroradiol. 2016 Dec;37(12):2340-2347
pubmed: 27469211
Pediatr Radiol. 2017 Sep;47(10):1345-1352
pubmed: 28526896
Clin Radiol. 2018 Mar;73(3):290-295
pubmed: 29208312
Invest Radiol. 2015 Dec;50(12):805-10
pubmed: 26523910
Eur Radiol. 2017 Jul;27(7):2877-2885
pubmed: 27832312
Neurology. 2017 Mar 21;88(12):1206-1208
pubmed: 28202695
Radiology. 2015 Sep;276(3):836-44
pubmed: 26079490
Radiology. 2018 Aug;288(2):424-433
pubmed: 29786486
J Trace Elem Med Biol. 2018 Jan;45:125-130
pubmed: 29173468
Radiology. 2015 Jun;275(3):783-91
pubmed: 25848905
Br J Radiol. 2016 Oct;89(1066):20160509
pubmed: 27459250
Invest Radiol. 2019 Sep;54(9):531-536
pubmed: 31261291
Radiology. 2017 Jun;283(3):828-836
pubmed: 28273007
Invest Radiol. 2018 Apr;53(4):214-222
pubmed: 29166300
Invest Radiol. 2019 Oct;54(10):617-626
pubmed: 31033673
Invest Radiol. 2017 Jun;52(6):324-333
pubmed: 28323657
Neuroradiology. 2019 May;61(5):535-544
pubmed: 30710184
Invest Radiol. 2016 Jul;51(7):447-53
pubmed: 26863577
Invest Radiol. 2017 Jul;52(7):396-404
pubmed: 28125438
Eur Radiol. 2016 Mar;26(3):807-15
pubmed: 26105022
Radiology. 2015 Jul;276(1):228-32
pubmed: 25942417
Eur Radiol. 2016 Nov;26(11):4080-4088
pubmed: 26911888
Eur Radiol. 2019 Aug;29(8):3959-3967
pubmed: 30413951
AJNR Am J Neuroradiol. 2016 Aug;37(8):1427-31
pubmed: 27032972
J Neuroimaging. 2017 Jul;27(4):372-375
pubmed: 28569398
Pediatr Radiol. 2016 Oct;46(11):1590-8
pubmed: 27282825
Eur Radiol. 2016 Dec;26(12):4577-4584
pubmed: 26905870
AJNR Am J Neuroradiol. 2015 Oct;36(10):1859-65
pubmed: 26294649
Magn Reson Med Sci. 2017 Jan 10;16(1):84-86
pubmed: 27725576
Radiology. 2017 Feb;282(2):516-525
pubmed: 27513848
Radiology. 2017 Mar;282(3):699-707
pubmed: 27925871
Radiology. 2015 Jun;275(3):772-82
pubmed: 25742194
Invest Radiol. 2015 Nov;50(11):743-8
pubmed: 26352749
Mult Scler. 2017 Jun;23(7):963-972
pubmed: 27679460
Brain Dev. 2016 Mar;38(3):331-6
pubmed: 26345358
Pediatrics. 2015 Dec;136(6):e1637-40
pubmed: 26574593
Radiology. 2017 Jan;282(1):222-228
pubmed: 27467467
Invest Radiol. 2018 May;53(5):278-285
pubmed: 29319556
AJR Am J Roentgenol. 2016 Feb;206(2):414-9
pubmed: 26700156
Invest Radiol. 2016 Nov;51(11):677-682
pubmed: 27272543
Invest Radiol. 2015 Jul;50(7):470-2
pubmed: 25756685
Invest Radiol. 2016 Feb;51(2):83-9
pubmed: 26606548
Invest Radiol. 2017 May;52(5):255-264
pubmed: 28067754
Eur Neurol. 2016;75(3-4):195-8
pubmed: 27054693
Brain Behav Immun. 2017 Feb;60:1-12
pubmed: 26995317
Mol Imaging Biol. 2013 Apr;15(2):148-54
pubmed: 22811020

Auteurs

Henning Richter (H)

Diagnostic Imaging Research Unit (DIRU), Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.

Patrick Bücker (P)

Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany.

Calvin Dunker (C)

Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany.

Uwe Karst (U)

Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany.

Patrick Robert Kircher (PR)

Diagnostic Imaging Research Unit (DIRU), Clinic for Diagnostic Imaging, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH